// App-Quantinova.ai

: Preliminary results of a two stage phase II study of 18F-DCFPyL PET-MR for enabling oligometastases ablative therapy in subclinical prostate cancer.

Researchers

Presenter

  • Rachel Glicksman

Principal Investigators

  • Doug Vines

  • Rosanna Chan

  • John Valliant

  • Peter W. M. Chung

  • Mary K. Gospodarowicz

  • Andrew Bayley

  • Charles N Catton

  • Padraig Richard Warde

  • Joelle Antoine Helou

  • Nafisha Lalani

  • David E Green

  • Nathan Perlis

  • Neil Eric Fleshner

  • Robert James Hamilton

  • Alexandre Zlotta

  • Antonio Finelli

  • David A. Jaffray

  • Alejandro Berlin

Medical Centers

  • Department of Surgery, University of Toronto, Toronto, ON, Canada

  • Joint Department of Medical Imaging, University of Toronto Health Network, Toronto, ON, Canada

  • Department of Radiation Oncology, University of Toronto, Toronto, Canada

  • Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

  • Centre for Probe Development and Commercialization, Chemistry and Chemical Biology, McMaster University, Hamilton, ON, Canada

  • Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

  • Rheumatology, Toronto Western Research Institute. University of Toronto, Toronto, ON, Canada

  • Department of Surgery, Division of Urology, University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • 18F-DCFPyL

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT03160794

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved